Kinetic Imaging Cytometer (KIC) for High Throughput Studies of Cellular Physiology

项目总结/摘要： 斯坦福大学心血管研究所（CVI）提议收购Vala Sciences的IC 200 动态成像细胞仪（KIC）将被放置在新的生物医学 创新（BMI）大楼位于校园中心。IC 200 KIC是一款前沿产品， 一种将高容量放映系统与高速视频相结合的仪器 生理记录仪器的成像和逐细胞分析特征， 膜片钳电生理学设置。没有任何其他类型的仪器结合了这些功能， 在斯坦福大学校园或附近没有类似的仪器。仪器将 用于深入研究，探索可兴奋细胞的疾病机制，如 在前所未有的全基因组和全蛋白质组水平上研究心肌细胞。重点 基于机制的疾病的理解，并最终发展的机制- 基于治疗，符合斯坦福大学CVI和学校的长期战略计划， 医学，与最近的教师招聘相一致。高通量的能力 评估心脏细胞的生理功能在这个计划中起着中心作用。仪器 将由一个经验丰富的小组管理，该小组具有高内容筛选和疾病方面的专业知识 使用基于诱导多能干细胞（iPSC）的模型进行建模。CVI包括更多 400多名研究人员和125多个教师领导的研究小组，跨越不同的 包括内科、儿科、眼科和生物医学工程。的 本建议书中强调的主要用户和次要用户包括刚开始工作的初级教师 他们自己的实验室建立了超过20年的研究经验的正教授。 所有的主要用户都有NIH的资金，NIH赠款的集体收益包括 仪器预期用户时间的80%。该机构正在承诺相当大的 财政资源和专用空间，以确保 该仪器，包括其集成到机器人设施。我们预计，IC 200将 积极影响广泛的心血管和其他疾病，特别是心力衰竭 糖尿病和癌症治疗的心血管并发症。此外，高 IC 200的通量和生理记录方面将推动我们的药物研究 发展和我们的翻译目标，改善心血管疾病患者的护理。

PROJECT SUMMARY/ABSTRACT: The Stanford Cardiovascular Institute (CVI) proposes the acquisition of a Vala Sciences’ IC200 Kinetic Imaging Cytometer (KIC) to be placed in a shared setting in the new Biomedical Innovations (BMI) Building that is centrally located on campus. The IC200 KIC is a cutting edge instrument that combines aspects of high content screening systems with high speed video imaging and cell-by-cell analysis features of physiological recording instrumentation such as patch clamp electrophysiology setups. No other type of instrument combines these features, and no comparable instrument is available on Stanford campus or in the vicinity. The instrument will be used for in-depth studies that probe disease mechanisms of excitable cells such as cardiomyocytes on an unprecedented whole genome and whole proteome level. The focus on mechanism-based understanding of disease, and ultimately the development of mechanism- based therapeutics, aligns with the long-term strategic plan of the Stanford CVI and School of Medicine, and is consistent with recent faculty recruitment. The capability of high throughput assessment of physiological function of heart cells plays a central role in this plan. The instrument will be managed by an experienced group with expertise in high content screening and disease modelling using induced pluripotent stem cell (iPSC)-based models. The CVI comprises more than 400 investigators and more than 125 faculty-led research groups and spans diverse departments including Medicine, Pediatrics, Ophthalmology and Biomedical Engineering. The Major and Minor Users highlighted in this proposal range from junior faculty who are just starting their own laboratories to established full professors with over 20 years of research experience. All the major users have NIH funding, and the collective benefit to NIH grants comprises over 80% of the anticipated user time of the instrument. The institution is committing considerable financial resources and dedicated space to ensure the maintenance and continued operation of the instrument, including its integration into a robotics facility. We expect that the IC200 will positively impact a broad cross section of cardiovascular and other diseases, notably heart failure and cardiovascular complications of diabetes and cancer treatments. In addition, the high throughput and physiology recording aspects of the IC200 will propel research towards our drug development and our translational goal of improving care of patients with cardiovascular disease.